Liver Cancer (Jul 2022)

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

  • Masatoshi Kudo

DOI
https://doi.org/10.1159/000526163
Journal volume & issue
Vol. 11, no. 5
pp. 399 – 406

Abstract

Read online

No abstracts available.

Keywords